Notice of Closed Meeting, 2618-2619 [2024-00675]

Download as PDF 2618 Federal Register / Vol. 89, No. 10 / Tuesday, January 16, 2024 / Notices data, training screeners, conducting the oral health screening at schools or Head Start sites. Screeners record four data points either electronically or on a paper form: (1) presence of treated caries; (2) presence of untreated tooth decay; (3) urgency of need for treatment; and (4) presence of dental sealants on at least one permanent molar tooth. State programs enter, clean and analyze the data; de-identify it; and respond to ASTDD’s annual email request for State-aggregated prevalence of dental caries and sealants. ASTDD reviews the data to ensure that both survey design and data meet specific criteria before sending it to CDC for publication on the CDC’s public-facing Oral Health Data website (www.cdc.gov/ oralhealthdata). BSS for children serves as a key State oral health surveillance data source and facilitates State capacity to: (1) monitor children’s oral health status, trends, and disparities, and compare with other States; (2) inform planning, implementation and evaluation of effective oral health programs and policies; (3) measure State progress toward Healthy People objectives; and (4) educate the public and policy makers regarding cross-cutting public health programs. CDC also uses the data to evaluate performance of CDC oral health funding recipients. The estimated total annualized burden hours for the survey across the 34 States over the three years of this request are 40,207. There are no costs to children respondents other than their time. ESTIMATED ANNUALIZED BURDEN HOURS Number of responses per respondent Average burden per response (in hours) Total burden (in hours) Form name Child ..................................... Parent/caretaker .................. Screener .............................. School/site ........................... State Official ........................ Screening form ................................................ Consent ........................................................... Screening form ................................................ Participation form ............................................ Data Submission form ..................................... 150,370 150,370 301 2,890 34 1 1 1 1 1 5/60 1/60 666/60 68/60 32,742/60 12,531 2,506 3,341 3,275 18,554 Total .............................. .......................................................................... ........................ ........................ ...................... 40,207 Jeffrey M. Zirger, Lead, Information Collection Review Office, Office of Public Health Ethics and Regulations, Office of Science, Centers for Disease Control and Prevention. [FR Doc. 2024–00654 Filed 1–12–24; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Notice of Closed Meeting ddrumheller on DSK120RN23PROD with NOTICES1 Number of respondents Type of respondents Pursuant to 5 U.S.C. 1009(d), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended, and the Determination of the Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, CDC, pursuant to Public Law 92–463. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)–RFA–PS–24–039 Improving the Quality of Life of People with VerDate Sep<11>2014 18:57 Jan 12, 2024 Jkt 262001 HIV Aged 50 Years and Older in the United States, and RFA–PS–24–042 A Bridge to Adherence: Long-Acting Antiretroviral Therapy for People with HIV Released from Prison. Dates: May 1–2, 2024. Times: 10 a.m.–5 p.m., EDT. Place: Videoconference. Agenda: To review and evaluate grant applications. For Further Information Contact: Seraphine Pitt Barnes, Ph.D., M.P.H, C.H.E.S., Scientific Review Officer, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop H24–6, Atlanta, Georgia 30329–4027. Telephone: (770) 488–6115; Email: SPittBarnes@cdc.gov. The Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Kalwant Smagh, Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention. [FR Doc. 2024–00676 Filed 1–12–24; 8:45 am] BILLING CODE 4163–18–P PO 00000 Frm 00037 Fmt 4703 Sfmt 4703 DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Notice of Closed Meeting Pursuant to 5 U.S.C. 1009(d), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended, and the Determination of the Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, CDC, pursuant to Public Law 92–463. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel; (SEP)–RFA–IP–24–046, Nationwide Cohort to Estimate Burden of Respiratory Viruses and Immunologic Response (Blood Donor Cohort). Dates: April 11–12, 2024. Times: 10 a.m.–5 p.m., EDT. Place: Videoconference. Agenda: To review and evaluate grant applications. For Further Information Contact: Gregory Anderson, M.S., M.P.H, Scientific Review Officer, National Center for HIV, Viral E:\FR\FM\16JAN1.SGM 16JAN1 Federal Register / Vol. 89, No. 10 / Tuesday, January 16, 2024 / Notices Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop H24–6, Atlanta, Georgia 30329–4027. Telephone: (404) 718– 8833; Email: GAnderson@cdc.gov. The Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Kalwant Smagh, Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention. [FR Doc. 2024–00675 Filed 1–12–24; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention [Docket No. CDC–2024–0001] Advisory Committee on Immunization Practices Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). ACTION: Notice and request for comment. AGENCY: In accordance with regulatory provisions, the Centers for Disease Control and Prevention (CDC) announces the following meeting of the Advisory Committee on Immunization Practices (ACIP). This meeting is open to the public. Time will be available for public comment. DATES: The meeting will be held on February 28, 2024, from 8 a.m. to 5 p.m., EST and February 29, 2024, from 8 a.m. to 3 p.m., EST, (times subject to change; see the ACIP website for updates: https://www.cdc.gov/vaccines/acip/ index.html). Written comments must be received between February 1–22, 2024. ADDRESSES: You may submit comments, identified by Docket No. CDC–2024– 0001, by either of the methods listed below. CDC does not accept comments by email. • Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. • Mail: Ms. Stephanie Thomas, ACIP Meeting, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop H24–8, Atlanta, Georgia 30329–4027. Attn: Docket No. CDC– 2024–0001. ddrumheller on DSK120RN23PROD with NOTICES1 SUMMARY: VerDate Sep<11>2014 18:57 Jan 12, 2024 Jkt 262001 Instructions: All submissions received must include the Agency name and docket number. All relevant comments received in conformance with the https://www.regulations.gov suitability policy will be posted without change to https://www.regulations.gov, including any personal information provided. For access to the docket to read background documents or comments received, go to https://www.regulations.gov. The meeting will be webcast live via the World Wide Web. The webcast link can be found on the ACIP website at https://www.cdc.gov/vaccines/acip/ index.html. FOR FURTHER INFORMATION CONTACT: Stephanie Thomas, Committee Management Specialist, Advisory Committee on Immunization Practices, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop H24–8, Atlanta, Georgia 30329–4027. Telephone: (404) 639–8836; Email: ACIP@cdc.gov. SUPPLEMENTARY INFORMATION: Purpose: The Advisory Committee on Immunization Practices (ACIP) is charged with advising the Director, Centers for Disease Control and Prevention (CDC), on the use of immunizing agents. In addition, under 42 U.S.C. 1396s, the Committee is mandated to establish and periodically review and, as appropriate, revise the list of vaccines for administration to vaccine-eligible children through the Vaccines for Children program, along with schedules regarding dosing interval, dosage, and contraindications to administration of vaccines. Further, under applicable provisions of the Affordable Care Act and section 2713 of the Public Health Service Act, immunization recommendations of ACIP that have been approved by the Director, CDC, and appear on CDC immunization schedules generally must be covered by applicable health plans. Matters To Be Considered: The agenda will include discussions on influenza vaccines, chikungunya vaccine, COVID– 19 vaccines, meningococcal vaccines, pneumococcal vaccines, polio vaccines, Human papillomavirus (HPV) vaccines, respiratory syncytial virus vaccines, a combined Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus influenzae Type B Conjugate, and Hepatitis B vaccine (Vaxelis®), and vaccines to prevent diphtheria, tetanus, and pertussis. Recommendation votes are scheduled for influenza vaccines, COVID–19 vaccines, and chikungunya vaccine. A Vaccines for Children (VFC) PO 00000 Frm 00038 Fmt 4703 Sfmt 4703 2619 vote is scheduled for vaccines to prevent diphtheria, tetanus, and pertussis. Agenda items are subject to change as priorities dictate. For more information on the meeting agenda, visit https://www.cdc.gov/vaccines/acip/ meetings/. Meeting Information: The meeting will be webcast live via the World Wide Web. For more information on ACIP, please visit the ACIP website: https:// www.cdc.gov/vaccines/acip/. Public Participation Interested persons or organizations are invited to participate by submitting written views, recommendations, and data. Please note that comments received, including attachments and other supporting materials, are part of the public record and are subject to public disclosure. Comments will be posted on https://www.regulations.gov. Therefore, do not include any information in your comment or supporting materials that you consider confidential or inappropriate for public disclosure. If you include your name, contact information, or other information that identifies you in the body of your comments, that information will be on public display. CDC will review all submissions and may choose to redact, or withhold, submissions containing private or proprietary information such as Social Security numbers, medical information, inappropriate language, or duplicate/ near-duplicate examples of a mass-mail campaign. CDC will carefully consider all comments submitted into the docket. Written Public Comment: The docket will be opened to receive written comments on February 1–22, 2024. Written comments must be received by February 22, 2024. Oral Public Comment: This meeting will include time for members of the public to make an oral comment. Oral public comment will occur before any scheduled votes, including all votes relevant to the ACIP’s Affordable Care Act and Vaccines for Children Program roles. Priority will be given to individuals who submit a request to make an oral public comment before the meeting according to the procedures below. Procedure for Oral Public Comment: All persons interested in making an oral public comment at the February 28–29, 2024, ACIP meeting must submit a request at https://www.cdc.gov/ vaccines/acip/meetings/ between February 1, 2024, and no later than 11:59 p.m., EST, February 22, 2024, according to the instructions provided. E:\FR\FM\16JAN1.SGM 16JAN1

Agencies

[Federal Register Volume 89, Number 10 (Tuesday, January 16, 2024)]
[Notices]
[Pages 2618-2619]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-00675]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Notice of Closed Meeting

    Pursuant to 5 U.S.C. 1009(d), notice is hereby given of the 
following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 
U.S.C., as amended, and the Determination of the Director, Office of 
Strategic Business Initiatives, Office of the Chief Operating Officer, 
CDC, pursuant to Public Law 92-463. The grant applications and the 
discussions could disclose confidential trade secrets or commercial 
property such as patentable material, and personal information 
concerning individuals associated with the grant applications, the 
disclosure of which would constitute a clearly unwarranted invasion of 
personal privacy.

    Name of Committee: Disease, Disability, and Injury Prevention 
and Control Special Emphasis Panel; (SEP)-RFA-IP-24-046, Nationwide 
Cohort to Estimate Burden of Respiratory Viruses and Immunologic 
Response (Blood Donor Cohort).
    Dates: April 11-12, 2024.
    Times: 10 a.m.-5 p.m., EDT.
    Place: Videoconference.
    Agenda: To review and evaluate grant applications.
    For Further Information Contact: Gregory Anderson, M.S., M.P.H, 
Scientific Review Officer, National Center for HIV, Viral

[[Page 2619]]

Hepatitis, STD, and TB Prevention, Centers for Disease Control and 
Prevention, 1600 Clifton Road NE, Mailstop H24-6, Atlanta, Georgia 
30329-4027. Telephone: (404) 718-8833; Email: [email protected].
    The Director, Office of Strategic Business Initiatives, Office 
of the Chief Operating Officer, Centers for Disease Control and 
Prevention, has been delegated the authority to sign Federal 
Register notices pertaining to announcements of meetings and other 
committee management activities, for both the Centers for Disease 
Control and Prevention and the Agency for Toxic Substances and 
Disease Registry.

Kalwant Smagh,
Director, Office of Strategic Business Initiatives, Office of the Chief 
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2024-00675 Filed 1-12-24; 8:45 am]
BILLING CODE 4163-18-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.